Premium
High‐dose chemotherapy with haematopoietic stem‐cell support in patients with poor prognosis, relapsed or refractory germ cell tumours
Author(s) -
ELHELW LOAIE M.,
NAIK JAY D.,
CHESTER JOHN D.,
JOFFE JOHNATHAN K.,
SELBY PETER J.,
COLEMAN ROBERT E.
Publication year - 2006
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2006.06389.x
Subject(s) - medicine , etoposide , chemotherapy , carboplatin , seminoma , germ cell tumors , salvage therapy , refractory (planetary science) , haematopoiesis , stem cell , gastroenterology , surgery , oncology , biology , cisplatin , genetics , astrobiology
OBJECTIVE To report our experience of high‐dose chemotherapy (HDC) with haematopoietic stem‐cell support (HSC) in patients with poor risk, relapsed or refractory germ cell tumours (GCTs), as this treatment might offer effective salvage for patients with disseminated GCTs. PATIENTS AND METHODS We retrospectively reviewed the medical records and database for 33 patients with GCT who were treated with HDC with HSC in our centres. RESULTS Thirty‐three patients were treated with either one or two cycles of carboplatin and etoposide‐based HDC with HSC support, between March 1990 and October 2003. Twenty‐six patients (79%) had nonseminomatous GCT, six seminoma (18%), and one (3%) a combined seminoma and teratoma. Twenty patients (60%) had previously had a clinical complete response after previous chemotherapy ± surgery for residual disease. Most patients were treated with HDC for relapsing (49%) or relative refractory disease (30%), but seven (21%) had HDC in the first partial remission. The complete response rate to HDC was 58%. There were two treatment‐related deaths (6%). As of April 2005, 18 patients were alive and disease‐free with a median (range) follow‐up of 72 (0.5–174) months. The 5‐year overall and progression‐free survival probabilities were 57% and 56%, respectively. The median (range) times to absolute neutrophil count recovery (≥500/µL) were 13 (9–24) and 12 (10–15) days, and for platelet count recovery (≥20 000/µL) were 16 (7–50) and 13 (11–17) days, in the first and second cycles, respectively. CONCLUSION The role of HDC with HSC support in metastatic GCTs remains controversial, and data from randomized controlled trials are needed. Our experience suggests that, in selected patients, this approach might be a useful form of salvage therapy.